// App-Quantinova.ai

9 : Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

Researchers

Presenter

  • Thierry Andre

Principal Investigators

  • Dominique Berton

  • Giuseppe Curigliano

  • Susan Ellard

  • Jose Manuel Trigo Prez

  • Hendrik-Tobias Arkenau

  • Cyril Abdeddaim

  • Victor Moreno

  • Wei Guo

  • Ellie Im

  • Naureen Starling

Medical Centers

  • Sorbonne University, Hôpital Saint-Antoine,Paris,France

  • GINECO and Institut de Cancerologie de lOuest (ICO) Rene Gauducheau, Saint-Herblain, France

  • Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Department of Oncology and Haemato-Oncology, University of Milano, Milan, Italy

  • BC Cancer Agency, Kelowna, BC, Canada

  • Medical Oncology Department, Hospital Ramon y Cajal, Madrid, Spain

  • Sarah Cannon Research Institute, London, United Kingdom

  • Centre de Lutte Contre le Cancer-Centre Oscar Lambret, Lille, France

  • Medical Oncology, START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, Spain

  • GlaxoSmithKline, Waltham, MA

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

Locations

  • France

  • Italy

  • Canada

  • Spain

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Dostarlimab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Cohort

Phase

  • I

Study Id's

  • NCT02715284

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved